Innovation “Crisis” And Health Care Reform: Lilly CEO Urges Change In Focus
This article was originally published in The Pink Sheet Daily
Lechleiter editorial, Chamber of Commerce appearance include warnings about adverse effects on innovation; “Odyssey Project” launched to press similar themes.
You may also be interested in...
Pharma Share Of Health Reform Cost Savings To Come From Drug Access, Compliance, Personalized Medicine
As stakeholders pledge to reduce health system growth by $2 trillion over 10 years, Rep. Dingell urges support for public plan; Sen. Grassley wants more “concrete” proposals, CBO score.
Biden’s incoming Secretary of Health is a fan of ‘march in’ rights as a cost-containment tool for medicines. Two hold-overs from Trump Presidency may slow him down.
US FDA’s workshop to discuss new ideas to assess the impact of the opioid REMS comes after the industry collaboration behind the REMS has deemed the task essentially impossible.